News
Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...
Pharmalittle: We’re watching Europe moving to reject Elevidys, a FDA panel on SSRI risks, and more
European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback